Theravance Biopharma, Inc. (TBPH) Stock Rating Reaffirmed by Cantor Fitzgerald
Cantor Fitzgerald reissued their buy rating on shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) in a research report report published on Tuesday morning. Cantor Fitzgerald currently has a $55.00 target price on the biopharmaceutical company’s stock.
TBPH has been the topic of a number of other research reports. Evercore ISI assumed coverage on shares of Theravance Biopharma in a report on Wednesday, August 16th. They set an outperform rating and a $45.00 target price on the stock. BidaskClub cut shares of Theravance Biopharma from a sell rating to a strong sell rating in a report on Wednesday, August 2nd. Zacks Investment Research raised shares of Theravance Biopharma from a sell rating to a hold rating in a report on Tuesday, September 5th. ValuEngine cut shares of Theravance Biopharma from a hold rating to a sell rating in a report on Tuesday, August 1st. Finally, Needham & Company LLC reaffirmed a buy rating on shares of Theravance Biopharma in a report on Wednesday, August 2nd. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The stock has an average rating of Hold and an average target price of $41.86.
Shares of Theravance Biopharma (TBPH) traded down 1.27% during midday trading on Tuesday, hitting $34.24. The company’s stock had a trading volume of 328,236 shares. The stock’s 50 day moving average is $29.57 and its 200-day moving average is $35.29. The firm’s market cap is $1.84 billion. Theravance Biopharma has a 52-week low of $23.15 and a 52-week high of $43.44.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/theravance-biopharma-inc-tbph-stock-rating-reaffirmed-by-cantor-fitzgerald/1598437.html.
In other news, SVP Frank Pasqualone purchased 4,000 shares of the firm’s stock in a transaction dated Monday, August 21st. The shares were purchased at an average price of $26.34 per share, with a total value of $105,360.00. Following the completion of the acquisition, the senior vice president now owns 213,180 shares in the company, valued at approximately $5,615,161.20. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Bradford J. Shafer sold 14,670 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total transaction of $451,395.90. Following the completion of the transaction, the executive vice president now directly owns 134,327 shares in the company, valued at approximately $4,133,241.79. The disclosure for this sale can be found here. In the last ninety days, insiders bought 20,000 shares of company stock worth $494,300. Insiders own 6.10% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. QS Investors LLC bought a new position in Theravance Biopharma in the second quarter valued at $100,000. Ameritas Investment Partners Inc. increased its stake in Theravance Biopharma by 1,494.3% in the first quarter. Ameritas Investment Partners Inc. now owns 3,635 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 3,407 shares during the last quarter. Aperio Group LLC bought a new position in Theravance Biopharma in the second quarter valued at $205,000. BNP Paribas Arbitrage SA increased its stake in Theravance Biopharma by 570.7% in the second quarter. BNP Paribas Arbitrage SA now owns 5,151 shares of the biopharmaceutical company’s stock valued at $205,000 after acquiring an additional 4,383 shares during the last quarter. Finally, Amalgamated Bank bought a new position in Theravance Biopharma in the second quarter valued at $214,000. 84.84% of the stock is currently owned by hedge funds and other institutional investors.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.